← Leaderboards
Kristopher Andrew Sarosiek
Harvard University D/B/A Harvard School Of Public Health
$4,572,197
Attributed
$4,572,197
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $715.8K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,572,197 · 4
By mechanism
R37$2,243,441 · 1
R01$1,403,600 · 1
R00$746,998 · 1
K99$178,158 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard University D/B/A Harvard School Of Public Health
Same institution · by research overlap
- Marwa Osman$42,220
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseCellsApoptosisApoptoticToxic EffectPathway InteractionsStressCancer CellIn VivoInnovationExhibitsChemotherapyCancerousChildCell DeathIn VitroRegulationBrainBax GeneAdultProtein FamilySignal TransductionMouse ModelAffect
Grant awards (16)
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients$354,647
R37 · FY2025 · CA · contact PI
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients$346,614
R37 · FY2024 · CA · contact PI
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients$90,053
R37 · FY2024 · CA · contact PI
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients$357,559
R37 · FY2023 · CA · contact PI
Identifying targetable apoptotic vulnerabilities for the treatment of AL amyloidosis$350,900
R01 · FY2023 · DK · contact PI
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients$364,856
R37 · FY2022 · CA · contact PI
Identifying targetable apoptotic vulnerabilities for the treatment of AL amyloidosis$350,900
R01 · FY2022 · DK · contact PI
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients$364,856
R37 · FY2021 · CA · contact PI
Identifying targetable apoptotic vulnerabilities for the treatment of AL amyloidosis$350,900
R01 · FY2021 · DK · contact PI
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients$364,856
R37 · FY2020 · CA · contact PI
Identifying targetable apoptotic vulnerabilities for the treatment of AL amyloidosis$350,900
R01 · FY2020 · DK · contact PI
Regulation of Apoptotic Priming and Competence in Healthy and Cancerous Cells$248,999
R00 · FY2019 · CA · contact PI
Regulation of Apoptotic Priming and Competence in Healthy and Cancerous Cells$249,000
R00 · FY2018 · CA · contact PI
Regulation of Apoptotic Priming and Competence in Healthy and Cancerous Cells$248,999
R00 · FY2017 · CA · contact PI
Regulation of apoptotic priming and competence in healthy and cancerous cells$87,653
K99 · FY2015 · CA · contact PI
Regulation of apoptotic priming and competence in healthy and cancerous cells$90,505
K99 · FY2014 · CA · contact PI